Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
Memo Therapeutics has raised €96M across 4 funding rounds from 15 investors, most recently a Series C round in May 2024. Based in Zurich, Switzerland; founded 2012; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2024-05-07 | Series C | €20M | Kurma Partners,Ysios Capital | View deal → |
| 2023-11-02 | Series C | €26M | Adjuvant Capital,Fresenius Medical Care Ventures,GF Group Holding,Pureos Bioventures,Red Alpine,Schroders Capital+3 more | View deal → |
| 2022-02-16 | Series B | €35M | Adjuvant Capital,Fresenius Medical Care Ventures,GF Group Holding,Swisscanto Invest,Verve Ventures,Vesalius Biocapital Partners+1 more | View deal → |
| 2020-11-06 | Series A | €14M | Redalpine | View deal → |
